Man Group’s VistaGen Therapeutics VTGN Stock Holding History

Man Group’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,338	Closed	-$54.1K	–	2388
2024 Q4	$54.1K	Buy	+18,338	New	+$51.6K	﹤0.01%	1946

Other funds holding VTGN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Man Group's VTGN Position: Q1 2025 in Review

Man Group sold out of VistaGen Therapeutics (VTGN) in Q1 2025, closing a stake of 18,338 shares — an estimated $54.1K sold.

Man Group first reported a position in VTGN in Q4 2024 and held it in 1 quarter. The position peaked at $54.1K in Q4 2024. 48 funds tracked by Wall St. Rank hold VTGN as of Q1 2025.

Man Group reported no remaining VistaGen Therapeutics position as of Q1 2025 after selling out during the quarter.
Man Group sold 18,338 VistaGen Therapeutics shares in Q1 2025, an estimated $54.1K.
Man Group first reported a position in VistaGen Therapeutics in Q4 2024 and held it in 1 quarter.
Man Group's VistaGen Therapeutics position peaked at $54.1K in Q4 2024.
48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.